---
figid: PMC4671322__npv01001
figlink: /pmc/articles/PMC4671322/figure/NPV010F1/
number: Fig. 1
caption: 'Molecular mechanisms underlying the oncogenic metabolic phenotype. Oncogenic
  pathway alterations driving the Warburg effect involve (i) activation of the PI3
  K/Akt/mTOR pathway driving a glycolytic state (light green arrows); (ii) pyruvate
  kinase induced negative regulation of glycolysis, which provides glycolytic intermediates
  necessary to facilitate macromolecular biosynthesis (orange arrows); and (iii) shunting
  of glucose through the pentose phosphate pathway to build redox potential (dark
  green arrows). In the first of these major metabolic alterations (light green arrows),
  PI3 K activates Akt, which stimulates aerobic glycolysis and enhances transcription
  factor expression including hypoxia-inducible factor 1 (HIF1) through the action
  of the mammalian target of rapamycin (mTOR). Expression of transcription factors
  including HIF1 and Oct 1 further drives a proglycolytic state by enhancing the activity
  of mitochondrial pyruvate dehydrogenase kinases, which shunt pyruvate back towards
  glycolysis and away from mitochondrial oxidative phosphorylation. In the second
  of these major metabolic alterations (orange arrows), C-myc-induced expression of
  cytosolic dimeric pyruvate kinase M2 functionally negatively regulates glycolysis,
  shunting free carbons back toward macromolecular biosynthesis, which supports cell
  proliferation. In the third major metabolic alteration, PKM2-mediated regulation
  of glycolysis also shunts glycolytic intermediates toward alternative carbon-consuming
  pathways (dark green arrows) including the pentose phosphate and hexosamine pathways,
  which generate reducing power in the form of NADPH. C–myc-driven conversion of glutamate
  to glutathione (GSH) and isocitrate dehydrogenase (IDH) mediated conversion of isocitrate
  to alpha-ketoglutarate (dark green arrows) also resulting in additional reducing
  power in the form of NADPH and GSH necessary to scavenge excess reactive oxygen
  species generation. Abbreviations: αKG, alpha-ketoglutarate; 2-HG, 2-hydroxyglutarate;
  AMPK, AMP-activated protein kinase; CHO, carbohydrate; EGFR, epidermal growth factor
  receptor; G6P, glucose-6-phosphate; GLUT, glucose transporter; GSH, glutathione;
  HIF, hypoxia-inducible factor; IDH, isocitrate dehydrogenase; IDH-mu, IDH-mutant;
  IGF-R1, insulin-like growth factor-1 receptor; MCT, monocarboxylic acid transporter;
  mTOR, mammalian target of rapamycin; NADPH, nicotinamide adenine dinucleotide phosphate;
  Oct 1, Octamer transcription factor 1; PI3 K, phosphoinositide 3-kinase; P53, tumor
  protein 53; PDGFR, platelet-derived growth factor receptor; PDH, pyruvate dehydrogenase;
  PDK, pyruvate dehydrogenase kinase; PEP, phosphoenolpyruvic acid; PKB, protein kinase
  B, also known as Akt; PKM2, pyruvate kinase-M2 isoenzyme; PPP, pentose phosphate
  pathway; PTEN, phosphatase and tensin homolog; RTK, receptor tyrosine kinase; TCA,
  tricarboxylic acid.'
pmcid: PMC4671322
papertitle: 'Glycemic modulation in neuro-oncology: experience and future directions
  using a modified Atkins diet for high-grade brain tumors.'
reftext: Roy E. Strowd, et al. Neurooncol Pract. 2015 Sep;2(3):127-136.
pmc_ranked_result_index: '189290'
pathway_score: 0.9719397
filename: npv01001.jpg
figtitle: Molecular mechanisms underlying the oncogenic metabolic phenotype
year: '2015'
organisms:
- Homo sapiens
ndex: ''
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC4671322__npv01001.html
  '@type': Dataset
  description: 'Molecular mechanisms underlying the oncogenic metabolic phenotype.
    Oncogenic pathway alterations driving the Warburg effect involve (i) activation
    of the PI3 K/Akt/mTOR pathway driving a glycolytic state (light green arrows);
    (ii) pyruvate kinase induced negative regulation of glycolysis, which provides
    glycolytic intermediates necessary to facilitate macromolecular biosynthesis (orange
    arrows); and (iii) shunting of glucose through the pentose phosphate pathway to
    build redox potential (dark green arrows). In the first of these major metabolic
    alterations (light green arrows), PI3 K activates Akt, which stimulates aerobic
    glycolysis and enhances transcription factor expression including hypoxia-inducible
    factor 1 (HIF1) through the action of the mammalian target of rapamycin (mTOR).
    Expression of transcription factors including HIF1 and Oct 1 further drives a
    proglycolytic state by enhancing the activity of mitochondrial pyruvate dehydrogenase
    kinases, which shunt pyruvate back towards glycolysis and away from mitochondrial
    oxidative phosphorylation. In the second of these major metabolic alterations
    (orange arrows), C-myc-induced expression of cytosolic dimeric pyruvate kinase
    M2 functionally negatively regulates glycolysis, shunting free carbons back toward
    macromolecular biosynthesis, which supports cell proliferation. In the third major
    metabolic alteration, PKM2-mediated regulation of glycolysis also shunts glycolytic
    intermediates toward alternative carbon-consuming pathways (dark green arrows)
    including the pentose phosphate and hexosamine pathways, which generate reducing
    power in the form of NADPH. C–myc-driven conversion of glutamate to glutathione
    (GSH) and isocitrate dehydrogenase (IDH) mediated conversion of isocitrate to
    alpha-ketoglutarate (dark green arrows) also resulting in additional reducing
    power in the form of NADPH and GSH necessary to scavenge excess reactive oxygen
    species generation. Abbreviations: αKG, alpha-ketoglutarate; 2-HG, 2-hydroxyglutarate;
    AMPK, AMP-activated protein kinase; CHO, carbohydrate; EGFR, epidermal growth
    factor receptor; G6P, glucose-6-phosphate; GLUT, glucose transporter; GSH, glutathione;
    HIF, hypoxia-inducible factor; IDH, isocitrate dehydrogenase; IDH-mu, IDH-mutant;
    IGF-R1, insulin-like growth factor-1 receptor; MCT, monocarboxylic acid transporter;
    mTOR, mammalian target of rapamycin; NADPH, nicotinamide adenine dinucleotide
    phosphate; Oct 1, Octamer transcription factor 1; PI3 K, phosphoinositide 3-kinase;
    P53, tumor protein 53; PDGFR, platelet-derived growth factor receptor; PDH, pyruvate
    dehydrogenase; PDK, pyruvate dehydrogenase kinase; PEP, phosphoenolpyruvic acid;
    PKB, protein kinase B, also known as Akt; PKM2, pyruvate kinase-M2 isoenzyme;
    PPP, pentose phosphate pathway; PTEN, phosphatase and tensin homolog; RTK, receptor
    tyrosine kinase; TCA, tricarboxylic acid.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - PAEP
  - PDK1
  - EGFR
  - DLD
  - SLC2A1
  - EPAS1
  - HIF1A
  - PDK2
  - PDK3
  - PDK4
  - PKM
  - MTOR
  - PTEN
  - AKT1
  - AKT2
  - PDGFRB
  - DLAT
  - ARNTL
  - PDHA1
  - PDHA2
  - ARNT
  - MYC
  - HIF3A
  - AKT3
  - ARNT2
  - PDHB
  - TP53
  - PDGFRA
  - PDHX
  - IGF1R
  - Glucose
  - Glutamine
  - Isocitrate
  - Pyruvate
  - Glutamate
  - Lactate
  - Cancer
genes:
- word: PEP
  symbol: PEP
  source: hgnc_alias_symbol
  hgnc_symbol: PAEP
  entrez: '5047'
- word: PDK
  symbol: PDK
  source: bioentities_symbol
  hgnc_symbol: PDK1
  entrez: '5163'
- word: EGFR
  symbol: EGFR
  source: hgnc_symbol
  hgnc_symbol: EGFR
  entrez: '1956'
- word: PDH
  symbol: PDH
  source: bioentities_symbol
  hgnc_symbol: DLD
  entrez: '1738'
- word: GLUT
  symbol: GLUT
  source: hgnc_prev_symbol
  hgnc_symbol: SLC2A1
  entrez: '6513'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: PDK
  symbol: PDK
  source: bioentities_symbol
  hgnc_symbol: PDK2
  entrez: '5164'
- word: PDK
  symbol: PDK
  source: bioentities_symbol
  hgnc_symbol: PDK3
  entrez: '5165'
- word: PDK
  symbol: PDK
  source: bioentities_symbol
  hgnc_symbol: PDK4
  entrez: '5166'
- word: PKM2
  symbol: PKM2
  source: hgnc_prev_symbol
  hgnc_symbol: PKM
  entrez: '5315'
- word: MTOR
  symbol: MTOR
  source: hgnc_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: PDH
  symbol: PDH
  source: bioentities_symbol
  hgnc_symbol: DLAT
  entrez: '1737'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNTL
  entrez: '406'
- word: PDH
  symbol: PDH
  source: bioentities_symbol
  hgnc_symbol: PDHA1
  entrez: '5160'
- word: PDH
  symbol: PDH
  source: bioentities_symbol
  hgnc_symbol: PDHA2
  entrez: '5161'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT
  entrez: '405'
- word: MYC
  symbol: MYC
  source: hgnc_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: AKT
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT2
  entrez: '9915'
- word: PDH
  symbol: PDH
  source: bioentities_symbol
  hgnc_symbol: PDHB
  entrez: '5162'
- word: p53
  symbol: p53
  source: hgnc_alias_symbol
  hgnc_symbol: TP53
  entrez: '7157'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: PDH
  symbol: PDH
  source: bioentities_symbol
  hgnc_symbol: PDHX
  entrez: '8050'
- word: IGF-1R
  symbol: IGF1R
  source: hgnc_symbol
  hgnc_symbol: IGF1R
  entrez: '3480'
chemicals:
- word: Glucose
  source: MESH
  identifier: D005947
- word: Glutamine
  source: MESH
  identifier: D005973
- word: Isocitrate
  source: MESH
  identifier: D007523
- word: Pyruvate
  source: MESH
  identifier: D011773
- word: Glutamate
  source: MESH
  identifier: D018698
- word: Lactate
  source: MESH
  identifier: D019344
diseases:
- word: Cancer
  source: ''
  identifier: ''
---
